STUDY OBJECTIVE: To compare costs associated with a physician-pharmacist collaborative intervention with costs of usual care. DESIGN: Cost analysis using health care utilization and outcome data from two prospective, cluster-randomized, controlled clinical trials. SETTING:Eleven community-based medical offices. PATIENTS: A total of 496 patients with hypertension; 244 were in the usual care (control) group and 252 were in the intervention group. MEASUREMENTS AND MAIN RESULTS: To compare the costs, we combined cost data from the two trials. Total costs included costs of provider time, laboratory tests, and antihypertensive drugs. Provider time was calculated based on an online survey of intervention pharmacists and the National Ambulatory Medical Care Survey. Cost parameters were taken from the Bureau of Labor Statistics for average wage rates, the Medicare laboratory fee schedule, and a publicly available Web site for drug prices. Total costs were adjusted for patient characteristics. Adjusted total costs were $774.90 in the intervention group and $445.75 in the control group (difference $329.16, p<0.001). In a sensitivity analysis, the difference in adjusted total costs between the two groups ranged from $224.27-515.56. The intervention cost required to have one additional patient achieve blood pressure control within 6 months was $1338.05, determined by the difference in costs divided by the difference in hypertension control rates between the groups ($329.16/24.6%). The cost over 6 months to lower systolic and diastolic blood pressure 1 mm Hg was $36.25 and $94.32, respectively. CONCLUSION: The physician-pharmacist collaborative intervention increased not only blood pressure control but also the cost of care. Additional research, such as a cost-benefit or a cost-minimization analysis, is needed to assess whether financial savings related to reduced morbidity and mortality achieved from better blood pressure control outweigh the cost of the intervention.
RCT Entities:
STUDY OBJECTIVE: To compare costs associated with a physician-pharmacist collaborative intervention with costs of usual care. DESIGN: Cost analysis using health care utilization and outcome data from two prospective, cluster-randomized, controlled clinical trials. SETTING: Eleven community-based medical offices. PATIENTS: A total of 496 patients with hypertension; 244 were in the usual care (control) group and 252 were in the intervention group. MEASUREMENTS AND MAIN RESULTS: To compare the costs, we combined cost data from the two trials. Total costs included costs of provider time, laboratory tests, and antihypertensive drugs. Provider time was calculated based on an online survey of intervention pharmacists and the National Ambulatory Medical Care Survey. Cost parameters were taken from the Bureau of Labor Statistics for average wage rates, the Medicare laboratory fee schedule, and a publicly available Web site for drug prices. Total costs were adjusted for patient characteristics. Adjusted total costs were $774.90 in the intervention group and $445.75 in the control group (difference $329.16, p<0.001). In a sensitivity analysis, the difference in adjusted total costs between the two groups ranged from $224.27-515.56. The intervention cost required to have one additional patient achieve blood pressure control within 6 months was $1338.05, determined by the difference in costs divided by the difference in hypertension control rates between the groups ($329.16/24.6%). The cost over 6 months to lower systolic and diastolic blood pressure 1 mm Hg was $36.25 and $94.32, respectively. CONCLUSION: The physician-pharmacist collaborative intervention increased not only blood pressure control but also the cost of care. Additional research, such as a cost-benefit or a cost-minimization analysis, is needed to assess whether financial savings related to reduced morbidity and mortality achieved from better blood pressure control outweigh the cost of the intervention.
Authors: Donald Lloyd-Jones; Robert J Adams; Todd M Brown; Mercedes Carnethon; Shifan Dai; Giovanni De Simone; T Bruce Ferguson; Earl Ford; Karen Furie; Cathleen Gillespie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; P Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary M McDermott; James Meigs; Dariush Mozaffarian; Michael Mussolino; Graham Nichol; Véronique L Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Véronique L Roger; Randall Stafford; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan D Wong; Judith Wylie-Rosett Journal: Circulation Date: 2009-12-17 Impact factor: 29.690
Authors: Donald M Lloyd-Jones; Martin G Larson; Eric P Leip; Alexa Beiser; Ralph B D'Agostino; William B Kannel; Joanne M Murabito; Ramachandran S Vasan; Emelia J Benjamin; Daniel Levy Journal: Circulation Date: 2002-12-10 Impact factor: 29.690
Authors: Danielle M Wentzlaff; Barry L Carter; Gail Ardery; Carrie L Franciscus; William R Doucette; Elizabeth A Chrischilles; Kurt A Rosenkrans; Lucinda M Buys Journal: J Clin Hypertens (Greenwich) Date: 2011-03-18 Impact factor: 3.738
Authors: Jeff E Borenstein; Geneen Graber; Emmanuel Saltiel; Joel Wallace; Seonyoung Ryu; Jackson Archi; Stephen Deutsch; Scott R Weingarten Journal: Pharmacotherapy Date: 2003-02 Impact factor: 4.705
Authors: Barry L Carter; Gail Ardery; Jeffrey D Dawson; Paul A James; George R Bergus; William R Doucette; Elizabeth A Chrischilles; Carrie L Franciscus; Yinghui Xu Journal: Arch Intern Med Date: 2009-11-23
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: JAMA Date: 2003-05-14 Impact factor: 56.272
Authors: Puttarin Kulchaitanaroaj; Barry L Carter; Amber M Goedken; Elizabeth A Chrischilles; John M Brooks Journal: Res Social Adm Pharm Date: 2014-08-01
Authors: Catherine G Derington; Jordan B King; Kelsey B Bryant; Blake T McGee; Andrew E Moran; William S Weintraub; Brandon K Bellows; Adam P Bress Journal: Curr Hypertens Rep Date: 2019-11-07 Impact factor: 5.369
Authors: Verughese Jacob; Sajal K Chattopadhyay; Anilkrishna B Thota; Krista K Proia; Gibril Njie; David P Hopkins; Ramona K C Finnie; Nicolaas P Pronk; Thomas E Kottke Journal: Am J Prev Med Date: 2015-11 Impact factor: 5.043
Authors: Linnea A Polgreen; Barry L Carter; Philip M Polgreen; Peter M Snyder; Daniel K Sewell; Emine O Bayman; Shelby L Francis; Jacob E Simmering; Christopher Parker; Rachel Finkelstein Journal: Contemp Clin Trials Date: 2020-10-07 Impact factor: 2.226
Authors: Barry L Carter; Christopher S Coffey; Elizabeth A Chrischilles; Gail Ardery; Dixie Ecklund; Brian Gryzlak; Mark W Vander Weg; Paul A James; Alan J Christensen; Christopher P Parker; Tyler Gums; Rachel J Finkelstein; Liz Uribe; Linnea A Polgreen Journal: Pharmacotherapy Date: 2015-06-25 Impact factor: 4.705
Authors: Linnea A Polgreen; Jayoung Han; Barry L Carter; Gail P Ardery; Christopher S Coffey; Elizabeth A Chrischilles; Paul A James Journal: Hypertension Date: 2015-11-02 Impact factor: 10.190
Authors: Barry L Carter; Barcey T Levy; Brian Gryzlak; Elizabeth A Chrischilles; Mark W Vander Weg; Alan J Christensen; Paul A James; Carol A Moss; Christopher P Parker; Tyler Gums; Rachel J Finkelstein; Yinghui Xu; Jeffrey D Dawson; Linnea A Polgreen Journal: Contemp Clin Trials Date: 2015-05-04 Impact factor: 2.226
Authors: Steven P Dehmer; Michael V Maciosek; Nicole K Trower; Stephen E Asche; Anna R Bergdall; Rachel A Nyboer; Patrick J O'Connor; Pamela A Pawloski; JoAnn M Sperl-Hillen; Beverly B Green; Karen L Margolis Journal: J Am Coll Clin Pharm Date: 2018-04-14